Oric Pharmaceuticals, Inc. (ORIC) stock
Close on Nov 11, 2026Market cap $932.87MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $932.87M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.45
- Dividend yield
- –
- Free cash flow yield
- -12.03%
Fundamentals
- Net income
- -$140.35M
- EPS, diluted
- -$1.35
- Free cash flow
- -$112.26M
- Book value per share
- $3.53
- Diluted shares
- 108M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $8.91
- Open
- $8.95
- Day's range
- $8.84 – $9.15
- Volume
- 773,284
- Average volume (20 days)
- 2,000,503
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.18
- 52-week range
- $7.23 – $14.68
- RSI (14 days)
- 37.7
- Volatility (1 year)
- 89.8%
- Relative volume
- 0.48×
- WACC
- 10.8%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ORIC | S&P 500 | Difference | ORIC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.9% | -2.4% | −22.5 pts | ||
| 3 months | -34.5% | -1.2% | −33.3 pts | ||
| Year to date | +10.0% | +12.3% | −2.3 pts | ||
| 1 year | -30.1% | +12.4% | −42.6 pts | ||
| 3 years | +44.2% | +78.8% | −34.6 pts | +13.0% | +21.4% |
| 5 years | -49.2% | +75.2% | −124.4 pts | -12.7% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Oric Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- News
- Results
- News
About Oric Pharmaceuticals
Pharmaceutical Preparations
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapies to overcome cancer resistance mechanisms. The company focuses on three therapeutic areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage pipeline features rinzimetostat, an allosteric inhibitor targeting the polycomb repressive complex 2 for advanced prostate cancer, and enozertinib, an oral inhibitor targeting specific epidermal growth factor receptor mutations in non-small cell lung cancer. Because its product candidates remain under clinical investigation, the company serves cancer patients with advanced solid tumors through clinical trials rather than commercial product sales.
Company profile, executives and historyOric Pharmaceuticals stock: common questions
What is Oric Pharmaceuticals's stock price?
ORIC closed at $9.00 on Nov 11, 2026, up 1.01% on the day. Over the past 52 weeks it traded between $7.23 and $14.68.
What is Oric Pharmaceuticals's market cap?
Oric Pharmaceuticals was worth $932.87M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ORIC's P/E ratio?
Oric Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.35), so it has no meaningful P/E ratio.
Does Oric Pharmaceuticals pay a dividend?
No. Oric Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Oric Pharmaceuticals report earnings next?
Oric Pharmaceuticals is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ORIC stock performed over the past year?
Including dividends, ORIC returned -30.1% over the past year, against +12.4% for the S&P 500.
How many ORIC shares are sold short?
11M shares were sold short at the latest FINRA report, 10.95% of the float, or 4.8 days of average trading volume.
Who are Oric Pharmaceuticals's competitors?
Companies most similar to Oric Pharmaceuticals by business, industry and size include AVBP, BBOT, ALXO, ERAS, APLM.
See a number that looks wrong?